Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2018

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation predominant, diarrhea predominant, and mixed. Our analysis focuses on IBS-D, the diarrhea predominant subtype. Limited treatment options are currently available for IBS and only a few drugs have secured an FDA approval for IBS-D. Treatment options include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), a 5-HTR modulator (Sebela Pharmaceuticals’ Lotronex), and two recently approved agents: Salix Pharmaceuticals’ Xifaxan, an antibiotic, and Allergan’s Viberzi, an opioid delta receptor antagonist.

Questions Answered

• What is the patient share of key therapies and brands by line of therapy in newly diagnosed IBS-D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-D patients?
• How have Xifaxan and Viberzi been integrated into the treatment algorithm?
• What percentage of IBS-D patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
• What percentage of IBS-D patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
• What are the product-level compliance and persistency rates among drug-treated patients with IBS-D?

Product Description

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.